http://www.maniacsolutions.com/innovative-marketing-solutions-california/
Gamma Medica-Ideas Wins Industry Award for Innovation of the World Congress on Medical Physics
Northridge, CA – (Marketwire – November 24, 2009) – Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital systems for molecular imaging, announced today that it has been awarded an Innovation Award for its new imaging system prototype that combines the molecular imaging (MI) imaging capability of single photon nuclear magnetic resonance imaging (MRI). The award was presented to the GMI in the 2009 World Congress on Medical Physics and Biomedical Engineering in Munich, Germany, which took place on September 7, 2009. The Innovation Award was one of three awards during the awards ceremony plenary. The World Congress on Medical Physics is the world's largest convention medical physics, which attracted over 3,000 attendees and featured more than 2,800 scientific presentations. GMI award was selected from more than 100 competing work nominated for the award.
Dr. Dirk Meier, chief scientist of Gamma Medica-Ideas accepted the Innovation Award on behalf of the GMR. By Dr. Meier, "The new dual-modality SPECT / MRI system that GMI has been a pioneer in establishing an entirely new mode that allows images that merges the high resolution anatomic imaging capabilities of MRI with the ability to image physiological SPECT in one instrument. This was not previously possible because the vacuum tubes in conventional cabinets detectors used in SPECT are not able to operate in magnetic fields. "Dr. Douglas Wagenaar, Gamma Medica-Ideas Research Director added:" This advance could significantly affect the future of medical imaging in many fields. An example that could have an impact on the diagnosis of vulnerable plaque. vulnerable plaque is thrombogenic plaque that is distinct from the calcification of the arterial wall that most people associate with heart attacks, and in fact is now involved 70% of cardiovascular events. vulnerable plaque ruptures spontaneously generated acute and often fatal results. With a dual SPECT-MRI system at the same time could use MRI to visualize the swelling and inflammation associated with the accumulation of plaque and SPECT to identify and locate specific molecular processes that underlie the disease, such as metabolism, activation of endothelial cells, and apoptosis in the cells are "acting" different from normal. "
Parts of the development of GMI were funded by the NIH Biomedical Imaging Institute (NIBIB) in the U.S., and by the Council Research in Norway. The research team includes experts from several key institutions in the United States, in particular: Dr. Orhan Nalcioglu (University of California, Irvine), who specializes in the physics of MRI systems, and Dr. Benjamin MW Tsui (Johns Hopkins University Medical Center), which specializes in the development of novel image reconstruction techniques.
Gamma Medica-Ideas is focusing on pre-clinical market for the introduction of its first product using the new technology. The company believes that the pre-clinical setting is a perfect environment to challenge the new imaging systems to develop optimized performance and demonstrate new technologies before launching large scale clinical applications. As such, it aims to expand its market leading range imaging products for pre-clinical product with the addition of MRI-SPECT in 2010. In the future, GM-I specific plans for clinical applications of technology such as breast cancer imaging, neurodegenerative diseases such as Alzheimer's and Parkinson's, and atherosclerotic plaque in the cardiovascular diseases, areas where it is believed that the technology will have a big impact.
About Gamma Medica-Ideas, Inc.
Gamma Medica-Ideas (GMI) designs, builds and systems imaging service based on new technologies to improve patient health through early diagnosis of disease, improve patient care and allow new drug discovery. GMI is dedicated to leading medical imaging into a new digital era with its unique sensor systems reading. The company basic technologies of digital images are also very promising for a new class of solutions for security and the securities markets. In pre-clinical space, GMI's FLEX Triumph ™ imaging platform is marketed for medical research and drug development. The FLEX Triumph system combines PET (LabPET ™) SPECT (X-SPECT ®) and CT (XO ™) modalities in the world's first system of triple modality. pre-clinical imaging GMI are distributed exclusively by GE Healthcare globally and in Japan by SII Nanotechnology, a company Seiko. In the clinical space, GMI offers LumaGEM ®, its dual headquarters molecular breast imaging (MBI) based on early diagnosis and treatment of breast cancer. The digital image processing technology gamma rays in LumaGEM offers significant advances in resolution and contrast, which has allowed the identification of millimeter sized breast cancers missed by mammography, especially in women with dense breast tissue. Visit www.gm-ideas.com.
About the Author
Innovative Marketing Mastery Part 3 – Ford Saeks